M Garrido-Estepa1, I León-Gómez2, R Herruzo3, R Cano2. 1. National Centre for Epidemiology. Carlos III Health Institute (ISCIII-CNE), Spain. Electronic address: mgarrido@isciii.es. 2. National Centre for Epidemiology. Carlos III Health Institute (ISCIII-CNE), Spain. 3. Preventive Medicine and Public Health, University School of Medicine, Autónoma University, Madrid, Spain.
Abstract
PURPOSE: Meningococcal C conjugate vaccine was included in December 2000 in the Spanish childhood vaccination at 2, 4 and 6 months of age. In 2006, routine vaccination was modified to two doses at 2 and 4-6 months and a booster dose during the second year of age. Additionally, successive catch-up campaigns were launched to extend protection to older groups. This study provides long-term information about the vaccine effectiveness (VE) and the impact of vaccination in meningococcal C disease epidemiology in Spain. METHODS: We assessed surveillance data from season 1996/97 to season 2012/13 to describe changes in incidence and lethality of the disease. The vaccine-effectiveness study covered all cases notified from January 1st of 2001 onwards and evaluated vaccine effectiveness in both routines and in catch-up campaigns. To investigate the decline in protection over time, we compared the vaccine effectiveness within 1 year and more than one year since vaccination. RESULTS: The incidence of meningococcal serogroup C disease decreased first in those age-groups targeted for vaccination. But after 2006/07 season the decrease in incidence was generalised. Vaccine effectiveness was high in all vaccination programmes, although 2, 4-6 months (+ booster dose) routine showed higher overall vaccine effectiveness than 2, 4 and 6 months routine (99.3% vs. 90.2%). VE >1 year since vaccination was lower in 2, 4 and 6 months compared to 2 and 4-6 months (+ booster) routine (81.4% vs. 89.1%). For catch-up campaigns, VE increased and loss of VE decreased with the age of administration. Overall VE was 94.83 (CI95%: 93.37, 95.97), 98.82 (CI95%: 97.96, 99.31) and 90.89 (CI95%: 87.79, 93.21) for ≤ 1 and >1 year since vaccination, respectively. CONCLUSIONS: The meningococcal C conjugate vaccination programme has been extremely successful in controlling the disease and continues to be evaluated and adapted to the changes in the epidemiology of the disease to ensure long-term vaccine protection.
PURPOSE:Meningococcal C conjugate vaccine was included in December 2000 in the Spanish childhood vaccination at 2, 4 and 6 months of age. In 2006, routine vaccination was modified to two doses at 2 and 4-6 months and a booster dose during the second year of age. Additionally, successive catch-up campaigns were launched to extend protection to older groups. This study provides long-term information about the vaccine effectiveness (VE) and the impact of vaccination in meningococcal C disease epidemiology in Spain. METHODS: We assessed surveillance data from season 1996/97 to season 2012/13 to describe changes in incidence and lethality of the disease. The vaccine-effectiveness study covered all cases notified from January 1st of 2001 onwards and evaluated vaccine effectiveness in both routines and in catch-up campaigns. To investigate the decline in protection over time, we compared the vaccine effectiveness within 1 year and more than one year since vaccination. RESULTS: The incidence of meningococcal serogroup C disease decreased first in those age-groups targeted for vaccination. But after 2006/07 season the decrease in incidence was generalised. Vaccine effectiveness was high in all vaccination programmes, although 2, 4-6 months (+ booster dose) routine showed higher overall vaccine effectiveness than 2, 4 and 6 months routine (99.3% vs. 90.2%). VE >1 year since vaccination was lower in 2, 4 and 6 months compared to 2 and 4-6 months (+ booster) routine (81.4% vs. 89.1%). For catch-up campaigns, VE increased and loss of VE decreased with the age of administration. Overall VE was 94.83 (CI95%: 93.37, 95.97), 98.82 (CI95%: 97.96, 99.31) and 90.89 (CI95%: 87.79, 93.21) for ≤ 1 and >1 year since vaccination, respectively. CONCLUSIONS: The meningococcal C conjugate vaccination programme has been extremely successful in controlling the disease and continues to be evaluated and adapted to the changes in the epidemiology of the disease to ensure long-term vaccine protection.
Authors: Volker Vetter; Roger Baxter; Gülhan Denizer; Marco A P Sáfadi; Sven-Arne Silfverdal; Andrew Vyse; Ray Borrow Journal: Expert Rev Vaccines Date: 2016-03-04 Impact factor: 5.217
Authors: Myint Tin Tin Htar; Sally Jackson; Paul Balmer; Lidia Cristina Serra; Andrew Vyse; Mary Slack; Margarita Riera-Montes; David L Swerdlow; Jamie Findlow Journal: BMC Public Health Date: 2020-12-09 Impact factor: 3.295
Authors: Giada Maria Di Pietro; Giulia Biffi; Massimo Luca Castellazzi; Claudia Tagliabue; Raffaella Pinzani; Samantha Bosis; Paola Giovanna Marchisio Journal: Int J Environ Res Public Health Date: 2022-03-29 Impact factor: 3.390